Middle East Conflict Impacts Australia and New Zealand Businesses 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
NEW YORK, May 02, 2018 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Edge Therapeutics, Inc. ("Edge Therapeutics") (NASDAQ:EDGE) between December 29, 2017 and March 27, 2018. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more information go to:
http://www.zlk.com/pslra-d/edge-therapeutics-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Edge Therapeutics lead product candidate EG-1962 would likely fail a futility analysis in connection with the NEWTON 2 study; and (2) as a result of the foregoing, the Company's financial statements and Defendants' statements about Edge's business, operations, and prospects, were materially false and misleading at all relevant times.
If you suffered a loss in Edge Therapeutics you have until June 22, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
